Sebastian Bruera

Jan 7, 2025 | digitalcommons.library.tmc.edu | Sebastian Bruera |Maria E. Suarez-Almazor

Keywordscheckpoint inhibitor therapy, glucocorticoids, immunosuppressants, cancer, immunotherapyAbstractThe emergence of checkpoint inhibitors has created a paradigm shift for the treatment of various malignancies. However, although these therapies are associated with improved survival rates, they also carry the risk of immune-related adverse events (irAEs).

Sep 4, 2024 | digitalcommons.library.tmc.edu | Sebastian Bruera |Xiudong Lei |Hui Zhao |Jinoos Yazdany

OBJECTIVES: We compared the outcomes of patients with or without systemic lupus erythematosus (SLE) who were diagnosed with coronavirus disease 19 (COVID-19) and evaluated factors within patients with SLE associated with severe outcomes. METHODS: This retrospective cohort study used the deidentified Optum COVID-19 electronic health record dataset to identify patients with COVID-19 from 1/1/2020 to 31/12/2020.

Feb 14, 2023 | lupus.bmj.com | Sebastian Bruera |Xiudong Lei |Hui Zhao |Jinoos Yazdany

DiscussionTo our knowledge, this is the first study using national EHR data in the USA to describe COVID-19 outcomes among patients with SLE compared with matched controls. Patients with SLE had a statistically significant increase in rates of mortality, mechanical ventilation, hospitalisation and ICU admissions without ventilation from COVID-19 from 1 January 2020 to 31 December 2020.